Business Wire

I-VASC Srl Announces achievement of 1,8M € Series A investment to launch its product, VELEX™, a device for the treatment of Chronic Venous Insufficiency (CVI)

Share

The Series A round has seen the participation of former shareholders and a significant contribution of new investors: Italian business angels, family office and others. I-VASC is planning to use the proceeds from this round to execute post-market clinical studies, to obtain FDA approval for the US market and complete product industrialization.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220404005835/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

VELEX™, A novel device for the treatment of Chronic Venous Insufficiency (CVI) (Photo: Business Wire)

I-VASC Srl, Italy based medical device company, which has conceived a new technology for the treatment of CVI and varicose veins named EVA (Empty Vein Ablation) and developed the VELEX ™ device based on this technology, has announced that it has successfully finalized its Series A financing round, oversubscribed by a high number of investors, including notably the Luca Trevisan, Bootes (Rosario Bifulco), and Nalini family Office, and others qualified investors. In addition to the 750K Euro tranche raised in the first half of 2021, the company has raised another 1.066M Euro tranche before the end of last year, for a total amount of 1.8M Euro in 2021. The proceeds from this round will be used by I-VASC to pay for post-market clinical studies of the VELEX ™ device (which has received CE Mark approval for the European market in May 2021), to move toward FDA regulatory approval for the US market, and consolidate industrialization throughout a supply chain of qualified suppliers. The company has also announced the appointments of two new Directors in its board to reinforce its management Team in this phase of strategic growth: Daniele Zanotti, who has assumed the role of CEO, and Cristiano Fontana, who has undertaken responsibility for business development, marketing and communication. Mario Salerno, founder of I-VASC and inventor of the EVA technology, will retain his active executive role and the functions of Chairman of the Board and President, while Emilio Roncoroni and Attilio Castelli from the previous board, will continue to exert their roles of Chief Administration and Chief Technology Officers, respectively.

“Thanks to the investors, who have believed in our proprietary and innovative technology, and to our reinforced team, we are now on the verge to bring VELEX™ into the market.”

VELEX™, I-VASC’s first CE Mark approved device, offers the innovative solution of the Empty Vein Ablation (EVA) technology for treating CVI, which notably includes the varicose veins disease.

VELEX™ innovation consists of a percutaneous 3-ballon catheter that allows to perform a chemical ablation (Schlerotherapy) into the portion of the vein to be treated after having isolated it and emptied it from blood. This method offers the ability of fully controlling schlerosant agent contact distribution and time, resulting into optimal ablation results. Besides, agent segregation, limited concentration and final retrieval may result also in superior safety, when compared to conventional schlerotherapy.

“I am thrilled to embrace this new professional adventure and put my experience at the service of a project which has the potential of representing a new paradigm in the largely underserved market of CVI and varicose vein. With the considerable efficacy, safety and usability improvements that VELEX can offer with respect to all alternative methods, we have the opportunity to offer a better option to millions of patients and create a huge new value in the vascular arena.” said Daniele Zanotti, newly appointed CEO of I-VASC.

“We are approaching a new and important phase of the project, which I started in 2015. Thanks to the investors, who have believed in our proprietary and innovative technology, and to our reinforced team, we are now on the verge to bring VELEX™ into the market and provide proof of the validity of our EVA (Empty Vein Ablation) procedure” said Mario Salerno, Founder and CMO of I-VASC.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries:
Ella Gilani
Executive assistant and Operations
e.gilani@i-vasc.com
+39 324 0873066
www.i-vasc.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Anterra Capital: Pandemic and Food Price Inflation Fuel Investor Interest to Accelerate Transformation of the Food and Ag Sector18.5.2022 07:00:00 CEST | Press release

A crushing pandemic and, more recently, the Ukraine war have convinced investors more than ever that the world needs to radically change how it produces, distributes and consumes food, says Adam Anders, managing partner of the international food and agriculture specialist venture capital firm Anterra Capital (“Anterra”). Anders: “The pandemic highlighted the fragility and adverse health impacts of our current food system: soaring prices, empty shelves in stores; the fact that unhealthy diets are a major risk factor for getting Covid; that the way we treat farm animals could trigger the next pandemic. Post our final closing, the devastating impact of the Ukraine War on the global food supply has increased the awareness among investors even further. This, plus our focus on deploying proven biotech and digital solutions to shake up the lagging Food and Ag-sector, go a long way in explaining the higher than expected interest in our second fund.” Anterra is proud to announce the closing of

US Streaming Technology Giant Conviva Launches Full-Scale Continuous Measurement Analytics in Japan18.5.2022 03:00:00 CEST | Press release

Conviva (Headquartered at Foster City, California, USA; Japan Office: Chiyoda-ku, Tokyo; hereinafter referred to as Conviva or the Company), which provides continuous measurement analytics through real-time, server side sessionization of video streaming data, today announced the opening of the Japan office, which will serve as a base for sales and customer support in the rapidly-growing Japanese market. The Company also released a current State of Streaming Report for Japan highlighting key streaming trends in the market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517006275/en/ Conviva State of Streaming Japan Report (Graphic: Business Wire) “Conviva invented continuous measurement analytics for streaming video and has been driving the development of the global market including Japan with over 58 technology patents over the past decade,” comments Conviva CEO Keith Zubchevich. “Today, we are pleased to announce the est

Starr Insurance Companies Expands in Thailand17.5.2022 22:33:00 CEST | Press release

Starr Insurance Companies (Starr) announced an agreement with FPG Insurance Holdings Limited (HK) (FPG) and local Thai shareholders to purchase FPG Insurance Public Company Limited (FPG Thailand), a Thai non-life insurance company, together with local Thai parties. Starr’s investment will be held by its Bermuda insurance company, Starr Insurance & Reinsurance Limited. The transaction is expected to close in the second quarter of 2022, subject to certain customary closing conditions, including any necessary regulatory approvals. “Thailand is an important, fast-growing insurance market — one of the cornerstones of the Southeast Asia economy,” said Maurice R. Greenberg, Starr’s Chairman & CEO. “Asia is both commercially and culturally important to Starr, as we trace our roots to an American-owned company founded in Shanghai more than 100 years ago. We look forward to serving the needs of local Thai companies and consumers through this new insurance capability.” David Zuellig, FPG regional

Emendo Biotherapeutics’ next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE -related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting17.5.2022 22:15:00 CEST | Press release

Emendo Biotherapeutics presented the results of its next generation CRISPR-based gene editing approaches for several indications in an oral presentation and three posters at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held May 16-19, 2022, in Washington, D.C. Emendo presented pre-clinical data for the treatment of ELANE-related Severe Congenital Neutropenia using an allele-specific editing approach, demonstrating the power of Emendo’s dual technology platforms that enable the development of a highly specific editing composition that demonstrates no off-targets and complete allele specificity. Significantly, the lack of off-target achieved by Emendo’s engineered and optimized OMNI nuclease also eliminated any translocations. Edited patient derived CD34+ cells differentiated normally into neutrophils both in-vitro and in-vivo, showing full engraftment and reconstitution of all blood lineages, as required for the desired therapeutic effect. “ELANE-based

Piper Sandler Advises PETRONAS Chemicals Group Berhad on Acquisition of Perstorp17.5.2022 19:59:00 CEST | Press release

Piper Sandler & Co. chemicals investment banking announced today that it has advised PETRONAS Chemicals Group Berhad (PCG) on its acquisition of Perstorp Holding AB. The transaction Enterprise Value is €2,300 million and base purchase price, less adjusted net debt, is €1,538 million. It is expected to close in Q3 2022 subject to customary closing conditions. PCG is the leading integrated chemicals producer in Malaysia and one of the largest in Southeast Asia. It operates a number of world-class production sites, which are fully vertically integrated from feedstock to downstream end-products. With a total combined production capacity of 12.8 million metric tons per annum (mtpa), it is involved primarily in manufacturing, marketing, and selling a diversified range of chemical products, including olefins, polymers, fertilizers, methanol and other basic chemicals and derivative products. Listed on Bursa Malaysia in 2010 and with more than three decades of experience in the chemicals indust

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom